Exciting news! Emblem announces a bought deal financing of $10,000,000

Toronto, ON -- January 9, 2017 -- InvestorsHub NewsWire -- Less than three weeks after listing on the TSX-V at $1.15 with an incredibly successful public offering and significant demand from the investment community, we’re more than thrilled to announce this latest funding round.

Priced at $3.63, our “Bought Deal” financing is being led by PI Financial, with 60% of the book, Canaccord Genuity with 20%, and GMP Securities with 20%. Although the announced offering was $10 million, due to significant demand, it is likely this will be increased. The offering comes with a callable half warrant priced at $4.75 for three years.

As you are aware, our approach from the very beginning has been dedicated to both our existing shareholders and to retail investors. In fact, 92% of all funds raised to date have been with retail investors.

As the investment community becomes more aware of our story and the benefits of investing in a company with three unique verticals (including Emblems industry unique pharmaceutical division, led by one of the top pharmaceutical executives in the world) the institutional community is more interested than ever in helping us advance our total business plan, including, in particular, our pharmaceutical division.

To truly build a world class company, and having just received our oils license in December, we have determined that it is in the best interest of shareholders to take on additional capital immediately, in order to completely build out our business with a particular focus on our pharmaceutical vertical.

The use of proceeds will include a significant investment for the construction of a 2,500 square-foot extraction and formulation development laboratory on our property in Paris, Ont. Additionally, we have hired a number of scientists to work exclusively in this division to pursue the development and manufacture of advanced dosage forms of cannabinoid medication.

This capital will now allow Emblem to bring to market a number of pharmaceutical formulations with advanced dosage formats, in a significantly shorter time period.

This offering allows us to continue to position ourselves in a market that includes Medical Dried Flower Marijuana, Cannabis Oils, Recreational Marijuana, and some of the largest pharmaceutical markets in Canada, namely chronic pain, anxiety and sleep disorders.

We are grateful for the support that our shareholders have provided to us. We are conscious of our obligation to reward the loyalty of our shareholders to the extent that it is in our power to do so. Consequently, we are striving to provide our current investors with an opportunity to participate in the current financing alongside the institutional investment community.

We appear to be significantly over-subscribed for this offering and there is limited availability for the Units being offered. However, we have made provision for a Presidents list.

If you are interested in participating in this offering, please send us an expression of interest by return email setting out the amount that you would like to invest in the offering. We will use our best efforts to include your prospective investment on our Presidents list.

Please note, with our apologies, we expect to be quite over-subscribed and we cannot confirm that expressions of interest will be filled in full, or at all. We will do our best.

Thank you again for your continued support.

Best regards,
Danny

Danny Brody, CIM

Director, Investor Relations

Investor Inquiries:
dannybrody@emblemcorp.com
(647) 255-8106

Patient Inquiries:
welcome@emblemcannabis.com
(519) 442-2220

Emblem Cannabis on Twitter

Emblem Cananbis on Facebook

Copyright © 2017 Emblem Corp, All rights reserved.
You are recieving this email because you expressed an interest in Emblem Corp.

Our mailing address is:

Emblem Corp

#207 - 1366 Yonge St

Toronto, On M4V 1L5

Canada

Emblem Corp (TSXV:EMC)
Historical Stock Chart
From Mar 2024 to Apr 2024